



Clinical trial results:

A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2016-004656-30 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 26 July 2016 |

Results information

| | |
|--------------------------------|----------------|
| Result version number | v1 (current) |
| This version publication date | 11 August 2017 |
| First version publication date | 11 August 2017 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | 1439-052 |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Merck Sharp & Dohme Corp. |
| Sponsor organisation address | 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033 |
| Public contact | Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com |
| Scientific contact | Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-001676-PIP01-14 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|--------------|
| Analysis stage | Final |
| Date of interim/final analysis | 26 July 2016 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 26 July 2016 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of the study are as follows: 1. To evaluate the comparative bioavailability of the MK-1439 100 mg adult formulation tablets under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated and coated granule formulation under fasting conditions; 2. To evaluate the comparative bioavailability of the MK-1439 100 mg oral pediatric uncoated granule formulation under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated granule formulation when given with vanilla pudding and with applesauce; 3. To evaluate the comparative bioavailability of the MK-1439 100 mg investigational oral pediatric coated granule formulation under fasting conditions to MK-1439 100 mg investigational oral pediatric uncoated granule formulation when given with vanilla pudding and with applesauce.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------|
| Actual start date of recruitment | 20 May 2016 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Canada: 24 |
| Worldwide total number of subjects | 24 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |

| | |
|----------------------|----|
| Adults (18-64 years) | 24 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

This is an open-label, single-dose, partially randomized, five-period, seven treatment, six-sequence, crossover, comparative bioavailability study. Each participant was assigned to 1 of 6 treatment sequences.

Pre-assignment

Screening details:

Study was to enroll healthy, non-smoking, male and female subjects, from 18 to 55 years of age. Other inclusion and exclusion criteria applied.

Period 1

| | |
|------------------------------|----------------|
| Period 1 title | Period 1 |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|------------------|----------------|
| Arm title | Sequence ABCWX |
|------------------|----------------|

Arm description: -

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 Adult formulation (Treatment A) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose administered after an overnight fast of at least 10 hours

| | |
|------------------|----------------|
| Arm title | Sequence ACBXW |
|------------------|----------------|

Arm description: -

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 Adult formulation (Treatment A) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose administered after an overnight fast of at least 10 hours

| | |
|------------------|----------------|
| Arm title | Sequence BACWX |
|------------------|----------------|

Arm description: -

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation (Treatment B) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered after an overnight fast of at least 10 hours

| | |
|--|--|
| Arm title | Sequence BCAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation (Treatment B) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of uncoated granules administered after an overnight fast of at least 10 hours | |
| Arm title | Sequence CABYZ |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation (Treatment C) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of coated granules administered after an overnight fast of at least 10 hours | |
| Arm title | Sequence CBAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation (Treatment C) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of coated granules administered after an overnight fast of at least 10 hours | |

| Number of subjects in period 1 | Sequence ABCWX | Sequence ACBXW | Sequence BACWX |
|---------------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |

| Number of subjects in period 1 | Sequence BCAZY | Sequence CABYZ | Sequence CBAZY |
|---------------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |

Period 2

| | |
|------------------------------|----------------|
| Period 2 title | Period 2 |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|----------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Sequence ABCWX |

Arm description: -

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg pediatric uncoated oral granules formulation (Treatment B) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered after an overnight fast of at least 10 hours

| | |
|------------------|----------------|
| Arm title | Sequence ACBXW |
|------------------|----------------|

Arm description: -

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation (Treatment C) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered after an overnight fast of at least 10 hours

| | |
|------------------|----------------|
| Arm title | Sequence BACWX |
|------------------|----------------|

Arm description: -

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 Adult formulation (Treatment A) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose administered after an overnight fast of at least 10 hours

| | |
|------------------|----------------|
| Arm title | Sequence BCAZY |
|------------------|----------------|

Arm description: -

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation (Treatment C) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered after an overnight fast of at least 10 hours

| | |
|--|---|
| Arm title | Sequence CABYZ |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 Adult formulation (Treatment A) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose administered after an overnight fast of at least 10 hours

| | |
|--|--|
| Arm title | Sequence CBAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation (Treatment B) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered after an overnight fast of at least 10 hours

| Number of subjects in period 2 | Sequence ABCWX | Sequence ACBXW | Sequence BACWX |
|--|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
| Suspected multiple study participation | - | - | - |

| Number of subjects in period 2 | Sequence BCAZY | Sequence CABYZ | Sequence CBAZY |
|--|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 |
| Not completed | 0 | 0 | 1 |
| Suspected multiple study participation | - | - | 1 |

Period 3

| | |
|------------------------------|----------------|
| Period 3 title | Period 3 |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|--|--|
| Arm title | Sequence ABCWX |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation (Treatment C) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of coated granules administered after an overnight fast of at least 10 hours | |
| Arm title | Sequence ACBXW |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation (Treatment B) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of uncoated granules administered after an overnight fast of at least 10 hours | |
| Arm title | Sequence BACWX |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation (Treatment C) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of coated granules administered after an overnight fast of at least 10 hours | |
| Arm title | Sequence BCAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 Adult formulation (Treatment A) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose administered after an overnight fast of at least 10 hours | |
| Arm title | Sequence CABYZ |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation (Treatment B) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |

| | |
|--|----------|
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose of uncoated granules administered after an overnight fast of at least 10 hours | |

| | |
|---|---|
| Arm title | Sequence CBAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 Adult formulation (Treatment A) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Single oral 100 mg dose administered after an overnight fast of at least 10 hours | |

| Number of subjects in period 3 | Sequence ABCWX | Sequence ACBXW | Sequence BACWX |
|--------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |

| Number of subjects in period 3 | Sequence BCAZY | Sequence CABYZ | Sequence CBAZY |
|--------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 3 |
| Completed | 4 | 4 | 3 |

| | |
|--|---|
| Period 4 | |
| Period 4 title | Period 4 |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |
| Arms | |
| Are arms mutually exclusive? | Yes |
| Arm title | Sequence ABCWX |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation with vanilla pudding (Treatment W) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered with vanilla pudding after an overnight fast of at least 10 hours

| | |
|--|--|
| Arm title | Sequence ACBXW |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation with applesauce (Treatment X) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered with apple sauce after an overnight fast of at least 10 hours

| | |
|--|---|
| Arm title | Sequence BACWX |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation with vanilla pudding (Treatment W) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered with vanilla pudding after an overnight fast of at least 10 hours

| | |
|--|--|
| Arm title | Sequence BCAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation with applesauce (Treatment Z) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered with apple sauce after an overnight fast of at least 10 hours

| | |
|--|---|
| Arm title | Sequence CABYZ |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation with vanilla pudding (Treatment Y) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered with vanilla pudding after an overnight fast of at least 10 hours

| | |
|--|--|
| Arm title | Sequence CBAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation with applesauce (Treatment Z) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered with apple sauce after an overnight fast of at least 10 hours

| Number of subjects in period 4 | Sequence ABCWX | Sequence ACBXW | Sequence BACWX |
|---------------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
| Adverse event, non-fatal | - | - | - |

| Number of subjects in period 4 | Sequence BCAZY | Sequence CABYZ | Sequence CBAZY |
|---------------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 3 |
| Completed | 4 | 4 | 2 |
| Not completed | 0 | 0 | 1 |
| Adverse event, non-fatal | - | - | 1 |

Period 5

| | |
|------------------------------|----------------|
| Period 5 title | Period 5 |
| Is this the baseline period? | No |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|--|--|
| Are arms mutually exclusive? | Yes |
| Arm title | Sequence ABCWX |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation with applesauce (Treatment X) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered with apple sauce after an overnight fast of

at least 10 hours

| | |
|--|---|
| Arm title | Sequence ACBXW |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated oral granules formulation with vanilla pudding (Treatment W) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered with vanilla pudding after an overnight fast of at least 10 hours

| | |
|--|---|
| Arm title | Sequence BACWX |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric uncoated granules formulation with applesauce (Treatment X) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of uncoated granules administered with apple sauce after an overnight fast of at least 10 hours

| | |
|--|---|
| Arm title | Sequence BCAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation with vanilla pudding (Treatment Y) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered with vanilla pudding after an overnight fast of at least 10 hours

| | |
|--|--|
| Arm title | Sequence CABYZ |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation with applesauce (Treatment Z) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered with apple sauce after an overnight fast of at least 10 hours

| | |
|--|---|
| Arm title | Sequence CBAZY |
| Arm description: - | |
| Arm type | Experimental |
| Investigational medicinal product name | MK-1439 100 mg (0.8 mg/granule) pediatric coated oral granules formulation with vanilla pudding (Treatment Y) |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Granules |
| Routes of administration | Oral use |

Dosage and administration details:

Single oral 100 mg dose of coated granules administered with vanilla pudding after an overnight fast of at least 10 hours

| Number of subjects in period 5 | Sequence ABCWX | Sequence ACBXW | Sequence BACWX |
|---------------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |

| Number of subjects in period 5 | Sequence BCAZY | Sequence CABYZ | Sequence CBAZY |
|---------------------------------------|----------------|----------------|----------------|
| Started | 4 | 4 | 2 |
| Completed | 4 | 4 | 2 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------|
| Reporting group title | Period 1 |
|-----------------------|----------|

Reporting group description:

All enrolled participants regardless of assigned sequence.

| Reporting group values | Period 1 | Total | |
|------------------------|----------|-------|--|
| Number of subjects | 24 | 24 | |
| Age Categorical | | | |
| Units: Subjects | | | |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 41 | | |
| standard deviation | ± 11 | - | |
| Gender Categorical | | | |
| Units: Subjects | | | |
| Female | 11 | 11 | |
| Male | 13 | 13 | |

End points

End points reporting groups

| | |
|--------------------------------|----------------|
| Reporting group title | Sequence ABCWX |
| Reporting group description: - | |
| Reporting group title | Sequence ACBXW |
| Reporting group description: - | |
| Reporting group title | Sequence BACWX |
| Reporting group description: - | |
| Reporting group title | Sequence BCAZY |
| Reporting group description: - | |
| Reporting group title | Sequence CABYZ |
| Reporting group description: - | |
| Reporting group title | Sequence CBAZY |
| Reporting group description: - | |
| Reporting group title | Sequence ABCWX |
| Reporting group description: - | |
| Reporting group title | Sequence ACBXW |
| Reporting group description: - | |
| Reporting group title | Sequence BACWX |
| Reporting group description: - | |
| Reporting group title | Sequence BCAZY |
| Reporting group description: - | |
| Reporting group title | Sequence CABYZ |
| Reporting group description: - | |
| Reporting group title | Sequence CBAZY |
| Reporting group description: - | |
| Reporting group title | Sequence ABCWX |
| Reporting group description: - | |
| Reporting group title | Sequence ACBXW |
| Reporting group description: - | |
| Reporting group title | Sequence BACWX |
| Reporting group description: - | |
| Reporting group title | Sequence BCAZY |
| Reporting group description: - | |
| Reporting group title | Sequence CABYZ |
| Reporting group description: - | |
| Reporting group title | Sequence CBAZY |
| Reporting group description: - | |
| Reporting group title | Sequence ABCWX |
| Reporting group description: - | |
| Reporting group title | Sequence ACBXW |
| Reporting group description: - | |
| Reporting group title | Sequence BACWX |
| Reporting group description: - | |
| Reporting group title | Sequence BCAZY |
| Reporting group description: - | |
| Reporting group title | Sequence CABYZ |
| Reporting group description: - | |
| Reporting group title | Sequence CBAZY |
| Reporting group description: - | |
| Reporting group title | Sequence ABCWX |
| Reporting group description: - | |
| Reporting group title | Sequence ACBXW |
| Reporting group description: - | |
| Reporting group title | Sequence BACWX |
| Reporting group description: - | |
| Reporting group title | Sequence BCAZY |
| Reporting group description: - | |
| Reporting group title | Sequence CABYZ |
| Reporting group description: - | |
| Reporting group title | Sequence CBAZY |

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Sequence ABCWX |
|-----------------------|----------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Sequence ACBXW |
|-----------------------|----------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Sequence BACWX |
|-----------------------|----------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Sequence BCAZY |
|-----------------------|----------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Sequence CABYZ |
|-----------------------|----------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Sequence CBAZY |
|-----------------------|----------------|

Reporting group description: -

| | |
|----------------------------|--|
| Subject analysis set title | MK-1439 Adult Tablet (Treatment A)- Pooled |
|----------------------------|--|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received single dose of 1 adult 100 mg tablet administered after an overnight fast of at least 10 hours regardless of assigned sequence.

| | |
|----------------------------|--|
| Subject analysis set title | Uncoated Granules (Treatment B) - Pooled |
|----------------------------|--|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received a single dose of 100 mg pediatric uncoated oral granules administered after an overnight fast of at least 10 hours regardless of assigned sequence.

| | |
|----------------------------|--|
| Subject analysis set title | Coated Granules (Treatment C) - Pooled |
|----------------------------|--|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received a single dose of 100 mg pediatric coated oral granules administered after an overnight fast of at least 10 hours regardless of assigned sequence.

| | |
|----------------------------|---|
| Subject analysis set title | Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled |
|----------------------------|---|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received 1 dose of 100 mg uncoated oral granules administered with vanilla pudding after an overnight fast of at least 10 hours regardless of assigned sequence

| | |
|----------------------------|---|
| Subject analysis set title | Uncoated Granules with Apple Sauce (Treatment X) - Pooled |
|----------------------------|---|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received 1 dose of 100 mg uncoated oral granules administered with apple sauce after an overnight fast of at least 10 hours regardless of assigned sequence

| | |
|----------------------------|---|
| Subject analysis set title | Coated Granules with Vanilla Pudding (Treatment Y) - Pooled |
|----------------------------|---|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received 1 dose of 100 mg coated oral granules administered with vanilla pudding after an overnight fast of at least 10 hours regardless of assigned sequence

| | |
|----------------------------|---|
| Subject analysis set title | Coated Granules with Apple Sauce (Treatment Z) - Pooled |
|----------------------------|---|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

All participants that received 1 dose of 100 mg coated oral granules administered with apple sauce after an overnight fast of at least 10 hours regardless of assigned sequence

Primary: Area Under the Concentration Curve from 0 to infinity (AUCinf) of MK-1439 Following Single Oral Dose Administration of 100 mg Adult Tablet, 100 mg Pediatric Uncoated Granules and 100 mg Pediatric Coated Granules Under Fasted Conditions

| | |
|-----------------|---|
| End point title | Area Under the Concentration Curve from 0 to infinity (AUCinf) of MK-1439 Following Single Oral Dose Administration of 100 mg Adult Tablet, 100 mg Pediatric Uncoated Granules and 100 mg Pediatric Coated Granules Under Fasted Conditions |
|-----------------|---|

End point description:

Blood samples drawn prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration to determine the AUCinf

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration

| End point values | MK-1439 Adult Tablet (Treatment A)- Pooled | Uncoated Granules (Treatment B) - Pooled | Coated Granules (Treatment C) - Pooled | |
|--|--|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 23 | 24 | 24 | |
| Units: hr·µM | | | | |
| geometric mean (confidence interval 95%) | 43.1 (37.7 to 49.3) | 39.6 (34.3 to 45.7) | 38.5 (33.9 to 43.7) | |

Statistical analyses

| | |
|-----------------------------------|------------------------------------|
| Statistical analysis title | Uncoated Granules vs. Adult Tablet |
|-----------------------------------|------------------------------------|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values

| | |
|---|---|
| Comparison groups | MK-1439 Adult Tablet (Treatment A)- Pooled v Uncoated Granules (Treatment B) - Pooled |
| Number of subjects included in analysis | 47 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | Geometric Mean Ratio (GMR) |
| Point estimate | 0.92 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.87 |
| upper limit | 0.97 |

| | |
|-----------------------------------|----------------------------------|
| Statistical analysis title | Coated Granules vs. Adult Tablet |
|-----------------------------------|----------------------------------|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on

natural log-transformed values

| | |
|---|---|
| Comparison groups | MK-1439 Adult Tablet (Treatment A)- Pooled v Coated Granules (Treatment C) - Pooled |
| Number of subjects included in analysis | 47 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.89 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.85 |
| upper limit | 0.94 |

Primary: Maximum Concentration (Cmax) of MK-1439 Following Single Oral Dose Administration of 100 mg Adult Tablet, 100 mg Pediatric Uncoated Granules and 100 mg Pediatric Coated Granules Under Fasted Conditions

| | |
|---|---|
| End point title | Maximum Concentration (Cmax) of MK-1439 Following Single Oral Dose Administration of 100 mg Adult Tablet, 100 mg Pediatric Uncoated Granules and 100 mg Pediatric Coated Granules Under Fasted Conditions |
| End point description: | |
| Blood samples drawn prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration to determine the AUCinf. | |
| End point type | Primary |
| End point timeframe: | |
| Prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration | |

| End point values | MK-1439 Adult Tablet (Treatment A)- Pooled | Uncoated Granules (Treatment B) - Pooled | Coated Granules (Treatment C) - Pooled | |
|--|--|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 23 | 24 | 24 | |
| Units: nM | | | | |
| geometric mean (confidence interval 95%) | 2100 (1880 to 2340) | 1950 (1780 to 2140) | 1610 (1440 to 1790) | |

Statistical analyses

| | |
|--|---|
| Statistical analysis title | Uncoated Granules vs. Adult Tablet |
| Statistical analysis description: | |
| Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | MK-1439 Adult Tablet (Treatment A)- Pooled v Uncoated Granules (Treatment B) - Pooled |

| | |
|---|---------------|
| Number of subjects included in analysis | 47 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.93 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.86 |
| upper limit | 1.01 |

| | |
|-----------------------------------|----------------------------------|
| Statistical analysis title | Coated Granules vs. Adult Tablet |
|-----------------------------------|----------------------------------|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values

| | |
|---|---|
| Comparison groups | MK-1439 Adult Tablet (Treatment A)- Pooled v Coated Granules (Treatment C) - Pooled |
| Number of subjects included in analysis | 47 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.77 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.7 |
| upper limit | 0.84 |

Primary: Concentration at 24 hours Post Dose (C24) of MK-1439 Following Single Oral Dose Administration of 100 mg Adult Tablet, 100 mg Pediatric Uncoated Granules and 100 mg Pediatric Coated Granules Under Fasted Conditions

| | |
|-----------------|--|
| End point title | Concentration at 24 hours Post Dose (C24) of MK-1439 Following Single Oral Dose Administration of 100 mg Adult Tablet, 100 mg Pediatric Uncoated Granules and 100 mg Pediatric Coated Granules Under Fasted Conditions |
|-----------------|--|

End point description:

Blood sample taken at 24 hours post dose to determine the concentration of MK-1439

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

24 hours post dose

| End point values | MK-1439 Adult Tablet (Treatment A)- Pooled | Uncoated Granules (Treatment B) - Pooled | Coated Granules (Treatment C) - Pooled | |
|--|--|--|--|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 23 | 24 | 24 | |
| Units: nM | | | | |
| geometric mean (confidence interval 95%) | 650 (556 to 759) | 622 (527 to 735) | 615 (541 to 700) | |

Statistical analyses

| Statistical analysis title | Uncoated Granules vs. Adult Tablet |
|---|---|
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | MK-1439 Adult Tablet (Treatment A)- Pooled v Uncoated Granules (Treatment B) - Pooled |
| Number of subjects included in analysis | 47 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.96 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.9 |
| upper limit | 1.02 |

| Statistical analysis title | Coated Granules vs. Adult Tablet |
|---|---|
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | MK-1439 Adult Tablet (Treatment A)- Pooled v Coated Granules (Treatment C) - Pooled |
| Number of subjects included in analysis | 47 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.95 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.89 |
| upper limit | 1.01 |

Primary: Area Under the Concentration Curve from 0 to infinity (AUCinf) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Uncoated Granules Alone, with Vanilla Pudding or with Apple Sauce

| | |
|-----------------|---|
| End point title | Area Under the Concentration Curve from 0 to infinity (AUCinf) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Uncoated Granules Alone, with Vanilla Pudding or with Apple Sauce |
|-----------------|---|

End point description:

Blood samples drawn prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration to determine the AUCinf

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration

| End point values | Uncoated Granules (Treatment B) - Pooled | Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled | Uncoated Granules with Apple Sauce (Treatment X) - Pooled | |
|--|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 24 | 12 | 12 | |
| Units: hr·µM | | | | |
| geometric mean (confidence interval 95%) | 39.6 (34.3 to 45.7) | 43.7 (37.1 to 51.5) | 51.2 (43.9 to 59.7) | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Uncoated Granules With Pudding vs Without |
|-----------------------------------|---|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values

| | |
|---|--|
| Comparison groups | Uncoated Granules (Treatment B) - Pooled v Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.1 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.02 |
| upper limit | 1.19 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Uncoated Granules With Apple Sauce vs Without |
|-----------------------------------|---|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects

model performed on natural log-transformed values

| | |
|---|--|
| Comparison groups | Uncoated Granules (Treatment B) - Pooled v Uncoated Granules with Apple Sauce (Treatment X) - Pooled |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.29 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.2 |
| upper limit | 1.39 |

Primary: Maximum Concentration (C_{max}) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Uncoated Granules Alone, with Vanilla Pudding or with Apple Sauce

| | |
|------------------------|--|
| End point title | Maximum Concentration (C _{max}) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Uncoated Granules Alone, with Vanilla Pudding or with Apple Sauce |
| End point description: | Blood samples drawn prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration to determine the C _{max} |
| End point type | Primary |
| End point timeframe: | Prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration |

| End point values | Uncoated Granules (Treatment B) - Pooled | Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled | Uncoated Granules with Apple Sauce (Treatment X) - Pooled | |
|--|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 24 | 12 | 12 | |
| Units: nM | | | | |
| geometric mean (confidence interval 95%) | 1950 (1780 to 2140) | 2030 (1750 to 2360) | 3040 (2750 to 3370) | |

Statistical analyses

| | |
|-----------------------------------|--|
| Statistical analysis title | Uncoated Granules With Pudding vs Without |
| Statistical analysis description: | Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values |
| Comparison groups | Uncoated Granules (Treatment B) - Pooled v Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled |

| | |
|---|---------------|
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.04 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.93 |
| upper limit | 1.17 |

| | |
|---|--|
| Statistical analysis title | Uncoated Granules With Apple Sauce vs Without |
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Uncoated Granules (Treatment B) - Pooled v Uncoated Granules with Apple Sauce (Treatment X) - Pooled |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.56 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.43 |
| upper limit | 1.7 |

Primary: Concentration at 24 hours Post Dose (C24) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Uncoated Granules Alone, with Vanilla Pudding or with Apple Sauce

| | |
|---|--|
| End point title | Concentration at 24 hours Post Dose (C24) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Uncoated Granules Alone, with Vanilla Pudding or with Apple Sauce |
| End point description: Blood sample drawn at 24 hours post dose to determine the C24 | |
| End point type | Primary |
| End point timeframe: 24 hours post dose | |

| End point values | Uncoated Granules (Treatment B) - Pooled | Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled | Uncoated Granules with Apple Sauce (Treatment X) - Pooled | |
|--|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 24 | 12 | 12 | |
| Units: nM | | | | |
| geometric mean (confidence interval 95%) | 622 (527 to 735) | 645 (539 to 773) | 743 (615 to 899) | |

Statistical analyses

| Statistical analysis title | Uncoated Granules With Pudding vs Without |
|---|--|
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Uncoated Granules (Treatment B) - Pooled v Uncoated Granules with Vanilla Pudding (Treatment W) - Pooled |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.04 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.95 |
| upper limit | 1.13 |

| Statistical analysis title | Uncoated Granules With Apple Sauce vs Without |
|---|--|
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Uncoated Granules (Treatment B) - Pooled v Uncoated Granules with Apple Sauce (Treatment X) - Pooled |
| Number of subjects included in analysis | 36 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.2 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.09 |
| upper limit | 1.31 |

Primary: Area Under the Concentration Curve from 0 to infinity (AUCinf) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Coated Granules Alone, with Vanilla Pudding or with Apple Sauce

| | |
|-----------------|---|
| End point title | Area Under the Concentration Curve from 0 to infinity (AUCinf) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Coated Granules Alone, with Vanilla Pudding or with Apple Sauce |
|-----------------|---|

End point description:

Blood samples drawn prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration to determine the AUCinf

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration

| End point values | Coated Granules (Treatment C) - Pooled | Coated Granules with Vanilla Pudding (Treatment Y) - Pooled | Coated Granules with Apple Sauce (Treatment Z) - Pooled | |
|--|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 24 | 10 | 11 | |
| Units: hr·µM | | | | |
| geometric mean (confidence interval 95%) | 38.5 (33.9 to 43.7) | 38.1 (32.3 to 44.9) | 48.4 (42.5 to 55.1) | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Coated Granules With Pudding vs Without |
|-----------------------------------|---|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values

| | |
|---|--|
| Comparison groups | Coated Granules (Treatment C) - Pooled v Coated Granules with Vanilla Pudding (Treatment Y) - Pooled |
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.99 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.91 |
| upper limit | 1.07 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Uncoated Granules With Apple Sauce vs Without |
|-----------------------------------|---|

Statistical analysis description:

Back-transformed least-squares mean difference and confidence interval from linear mixed-effects

model performed on natural log-transformed values

| | |
|---|--|
| Comparison groups | Coated Granules (Treatment C) - Pooled v Coated Granules with Apple Sauce (Treatment Z) - Pooled |
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.26 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.18 |
| upper limit | 1.34 |

Primary: Maximum Concentration (Cmax) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Coated Granules Alone, with Vanilla Pudding or with Apple Sauce

| | |
|--|---|
| End point title | Maximum Concentration (Cmax) of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Coated Granules Alone, with Vanilla Pudding or with Apple Sauce |
| End point description: | |
| Blood samples drawn prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration to determine the Cmax | |
| End point type | Primary |
| End point timeframe: | |
| Prior to dosing (0-hour) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24, 48, and 72 hours after drug administration | |

| End point values | Coated Granules (Treatment C) - Pooled | Coated Granules with Vanilla Pudding (Treatment Y) - Pooled | Coated Granules with Apple Sauce (Treatment Z) - Pooled | |
|--|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 24 | 10 | 11 | |
| Units: nM | | | | |
| geometric mean (confidence interval 95%) | 1610 (1440 to 1790) | 1460 (1230 to 1730) | 2560 (2390 to 2760) | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Coated Granules With Pudding vs Without |
| Statistical analysis description: | |
| Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Coated Granules (Treatment C) - Pooled v Coated Granules with Vanilla Pudding (Treatment Y) - Pooled |

| | |
|---|---------------|
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.9 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.79 |
| upper limit | 1.03 |

| | |
|---|--|
| Statistical analysis title | Coated Granules With Apple Sauce vs Without |
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Coated Granules (Treatment C) - Pooled v Coated Granules with Apple Sauce (Treatment Z) - Pooled |
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.59 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.47 |
| upper limit | 1.73 |

Primary: Concentration at 24 hours Post Dose (C24)of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Coated Granules Alone, with Vanilla Pudding or with Apple Sauce

| | |
|---|---|
| End point title | Concentration at 24 hours Post Dose (C24)of MK-1439 Following Single Oral Dose Administration of MK-1439 100 mg Pediatric Coated Granules Alone, with Vanilla Pudding or with Apple Sauce |
| End point description: Blood sample drawn at 24 hours after drug administration to determine the C24 | |
| End point type | Primary |
| End point timeframe: 24 hours post dose | |

| End point values | Coated Granules (Treatment C) - Pooled | Coated Granules with Vanilla Pudding (Treatment Y) - Pooled | Coated Granules with Apple Sauce (Treatment Z) - Pooled | |
|--|--|---|---|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 24 | 10 | 11 | |
| Units: nM | | | | |
| geometric mean (confidence interval 95%) | 615 (541 to 700) | 588 (502 to 689) | 745 (641 to 866) | |

Statistical analyses

| Statistical analysis title | Coated Granules With Pudding vs Without |
|---|--|
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Coated Granules (Treatment C) - Pooled v Coated Granules with Vanilla Pudding (Treatment Y) - Pooled |
| Number of subjects included in analysis | 34 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 0.96 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.88 |
| upper limit | 1.04 |

| Statistical analysis title | Coated Granules With Apple Sauce vs Without |
|---|--|
| Statistical analysis description: Back-transformed least-squares mean difference and confidence interval from linear mixed-effects model performed on natural log-transformed values | |
| Comparison groups | Coated Granules (Treatment C) - Pooled v Coated Granules with Apple Sauce (Treatment Z) - Pooled |
| Number of subjects included in analysis | 35 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| Parameter estimate | GMR |
| Point estimate | 1.21 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 1.12 |
| upper limit | 1.3 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

up to 14 days post last dose

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 19.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Treatment A |
|-----------------------|-------------|

Reporting group description:

All participants that received single dose of 1 adult 100 mg tablet administered after an overnight fast of at least 10 hours regardless of assigned sequence.

| | |
|-----------------------|-------------|
| Reporting group title | Treatment B |
|-----------------------|-------------|

Reporting group description:

All participants that received a single dose of 125 pediatric uncoated oral granules administered after an overnight fast of at least 10 hours regardless of assigned sequence.

| | |
|-----------------------|-------------|
| Reporting group title | Treatment C |
|-----------------------|-------------|

Reporting group description:

All participants that received a single dose of 125 pediatric coated oral granules administered after an overnight fast of at least 10 hours regardless of assigned sequence.

| | |
|-----------------------|-------------|
| Reporting group title | Treatment W |
|-----------------------|-------------|

Reporting group description:

All participants that received 1 dose of 125 uncoated oral granules administered with vanilla pudding after an overnight fast of at least 10 hours regardless of assigned sequence

| | |
|-----------------------|-------------|
| Reporting group title | Treatment X |
|-----------------------|-------------|

Reporting group description:

All participants that received 1 dose of 125 uncoated oral granules administered with apple sauce after an overnight fast of at least 10 hours regardless of assigned sequence

| | |
|-----------------------|-------------|
| Reporting group title | Treatment Y |
|-----------------------|-------------|

Reporting group description:

All participants that received 1 dose of 125 coated oral granules administered with vanilla pudding after an overnight fast of at least 10 hours regardless of assigned sequence

| | |
|-----------------------|-------------|
| Reporting group title | Treatment Z |
|-----------------------|-------------|

Reporting group description:

All participants that received 1 dose of 125 coated oral granules administered with apple sauce after an overnight fast of at least 10 hours regardless of assigned sequence

| Serious adverse events | Treatment A | Treatment B | Treatment C |
|---|----------------|----------------|----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| Serious adverse events | Treatment W | Treatment X | Treatment Y |
|------------------------------------|-------------|-------------|-------------|
| Total subjects affected by serious | | | |

| | | | |
|--|----------------|----------------|----------------|
| adverse events | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 10 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| Serious adverse events | Treatment Z | | |
|---|----------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Treatment A | Treatment B | Treatment C |
|---|----------------|-----------------|-----------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 7 / 24 (29.17%) | 7 / 24 (29.17%) |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 1 / 24 (4.17%) | 1 / 24 (4.17%) |
| occurrences (all) | 0 | 1 | 1 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 2 / 24 (8.33%) | 2 / 24 (8.33%) |
| occurrences (all) | 0 | 2 | 2 |
| General disorders and administration site conditions | | | |
| Catheter site related reaction | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 0 / 24 (0.00%) | 0 / 24 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoaesthesia oral | | | |

| | | | |
|--|---------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 23 (0.00%) 0 | 5 / 24 (20.83%) 5 | 4 / 24 (16.67%) 4 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 1 / 24 (4.17%) | 0 / 24 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 1 / 24 (4.17%) | 0 / 24 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 0 / 24 (0.00%) | 1 / 24 (4.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 23 (0.00%) | 0 / 24 (0.00%) | 1 / 24 (4.17%) |
| occurrences (all) | 0 | 0 | 1 |

| Non-serious adverse events | Treatment W | Treatment X | Treatment Y |
|---|----------------|-----------------|-----------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 5 / 12 (41.67%) | 3 / 10 (30.00%) |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 0 / 10 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 1 / 12 (8.33%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 1 | 1 |
| General disorders and administration site conditions | | | |
| Catheter site related reaction | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 12 (0.00%) | 1 / 10 (10.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |

| | | | |
|--|---------------------|----------------------|---------------------|
| Dry mouth subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 1 / 12 (8.33%) 1 | 0 / 10 (0.00%) 0 |
| Hypoaesthesia oral subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 4 / 12 (33.33%) 4 | 0 / 10 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 10 (0.00%) 0 |
| Throat irritation subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 10 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Erythema subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 10 (0.00%) 0 |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 12 (0.00%) 0 | 0 / 12 (0.00%) 0 | 0 / 10 (0.00%) 0 |

| | | | |
|--|---------------------|--|--|
| Non-serious adverse events | Treatment Z | | |
| Total subjects affected by non-serious adverse events subjects affected / exposed | 0 / 11 (0.00%) | | |
| Nervous system disorders | | | |
| Headache subjects affected / exposed occurrences (all) | 0 / 11 (0.00%) 0 | | |
| Somnolence subjects affected / exposed occurrences (all) | 0 / 11 (0.00%) 0 | | |
| General disorders and administration site conditions | | | |
| Catheter site related reaction subjects affected / exposed occurrences (all) | 0 / 11 (0.00%) 0 | | |
| Fatigue | | | |

| | | | |
|--|---------------------|--|--|
| subjects affected / exposed occurrences (all) | 0 / 11 (0.00%) 0 | | |
| Gastrointestinal disorders | | | |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypoaesthesia oral | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| occurrences (all) | 0 | | |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pruritus | | | |
| subjects affected / exposed | 0 / 11 (0.00%) | | |
| occurrences (all) | 0 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported